Zoetis (ZTS) Other Non-Current Assets (2012 - 2026)
Zoetis' (ZTS) quarterly Other Non-Current Assets came in at $351.0 million in Q1 2026, up 51.29% year-on-year from $232.0 million in Q1 2025, and up 7.34% on a QoQ basis from $327.0 million in Q4 2025.
Zoetis (ZTS) Other Non-Current Assets (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Other Non-Current Assets data on file, last reported at $351.0 million in Q1 2026.
- On a quarterly basis, Other Non-Current Assets rose 51.29% year-over-year to $351.0 million in Q1 2026; TTM through Mar 2026 was $351.0 million, a 51.29% increase from a year earlier, with the FY2025 full-year figure at $327.0 million, up 30.8% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $351.0 million, up from $327.0 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for ZTS reached as high as $351.0 million in Q1 2026 and fell as low as $129.0 million in Q1 2022.
- Historically, Other Non-Current Assets has averaged $224.1 million across 5 years, with a median of $216.0 million in 2023.
- Across the five-year window, Other Non-Current Assets soared 88.44% in 2024 and retreated 18.1% in 2025, its largest moves.
- Year by year, Other Non-Current Assets stood at $147.0 million in 2022, then soared by 40.14% to $206.0 million in 2023, then increased by 21.36% to $250.0 million in 2024, then surged by 30.8% to $327.0 million in 2025, then gained by 7.34% to $351.0 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $351.0 million in Q1 2026, $327.0 million in Q4 2025, and $293.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 49.22 Mn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 377.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 351.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 491.06 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 233.20 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | 169,000.00 |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.11 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 73.60 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 295.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 4.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 351.00 Mn |
| Dec 31, 2025 | 327.00 Mn |
| Sep 30, 2025 | 293.00 Mn |
| Jun 30, 2025 | 267.00 Mn |
| Mar 31, 2025 | 232.00 Mn |
| Dec 31, 2024 | 250.00 Mn |
| Sep 30, 2024 | 215.00 Mn |
| Jun 30, 2024 | 326.00 Mn |
| Mar 31, 2024 | 227.00 Mn |
| Dec 31, 2023 | 206.00 Mn |
| Sep 30, 2023 | 216.00 Mn |
| Jun 30, 2023 | 173.00 Mn |
| Mar 31, 2023 | 143.00 Mn |
| Dec 31, 2022 | 147.00 Mn |
| Sep 30, 2022 | 161.00 Mn |
| Jun 30, 2022 | 147.00 Mn |
| Mar 31, 2022 | 129.00 Mn |
| Dec 31, 2021 | 111.00 Mn |
| Sep 30, 2021 | 112.00 Mn |
| Jun 30, 2021 | 97.00 Mn |